What is already known about this subject:
To improve the efficacy, a combination drug therapy with ningetinib
and gefitinib was clinically proposed for the NSCLC treatment.
- N -demethyl ningetinib (M1) was identified as the primary
circulating metabolite in NSCLC patients whose plasma exposure was
about 1.7-fold that of the parent drug.
- When co-administered with gefitinib, the plasma exposure of M1 was
reduced by more than 80%. Contrary to expectations, pharmacokinetics
of ningetinib was not clearly affected.